R. Hayward

发表

Tumor Necrosis Factor-α Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited

R. Marais, V. Gray-Schopfer, M. Karasarides, 2007 .

CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation.

J. Hussain, C. Pritchard, R. Marais, 2008, Molecular cell.

Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies

Steven Whittaker, Richard Marais, S. Whittaker, 2010, Science Translational Medicine.

Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.

R. Marais, V. Gray-Schopfer, M. Karasarides, 2007, Cancer research.

B-RAF is a therapeutic target in melanoma

C. Marshall, C. Springer, R. Marais, 2004, Oncogene.

Poly(ADP-Ribose) Links the DNA Damage Response and Biomineralization

J. Skepper, Steven F. Lee, H. Oschkinat, 2019, Cell reports.

Poly(ADP-Ribose) Links the DNA Damage Response and Biomineralization

J. Skepper, Steven F. Lee, H. Oschkinat, 2019, Cell reports.

R. Hayward, C. Shanahan, A. Cobb, 2020, Arteriosclerosis, thrombosis, and vascular biology.

In situ characterization of advanced glycation end products (AGEs) in collagen and model extracellular matrix by solid state NMR† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7cc06624d

R. Li, R. Hayward, C. Shanahan, 2017, Chemical communications.

(V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis.

J. Reis-Filho, N. Dhomen, R. Marais, 2012, The Journal of investigative dermatology.

Prelamin A mediates myocardial inflammation in dilated and HIV-associated cardiomyopathies

M. Russo, A. Shah, E. Ehler, 2019, JCI insight.

Accumulation of prelamin A drives inflammation in the heart with implications for treatment of inherited and acquired cardiomyopathies

M. Russo, A. Shah, C. D. dos Remedios, 2018, bioRxiv.

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

S. Heidorn, L. Packer, B. Druker, 2011, Cancer cell.

Inducible expression of V600EBraf using tyrosinase‐driven Cre recombinase results in embryonic lethality

N. Dhomen, C. Springer, C. Pritchard, 2010, Pigment cell & melanoma research.

Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries

M. Jahangiri, M. Mayr, U. Mayr, 2018, Circulation.

Oncogenic Braf induces melanocyte senescence and melanoma in mice.

J. Reis-Filho, N. Dhomen, C. Pritchard, 2009, Cancer cell.

Tumor and Stem Cell Biology Cancer Research A Mouse Model of Melanoma Driven by Oncogenic KRAS

J. Reis-Filho, C. Milagre, N. Dhomen, 2010 .

BRAF inactivation drives aneuploidy by deregulating CRAF.

C. Pritchard, R. Marais, R. Hayward, 2010, Cancer research.

Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

E. Sahai, L. Packer, R. Marais, 2011, Cancer cell.

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

R. Marais, C. Wellbrock, I. Arozarena, 2012, Journal of the National Cancer Institute.

ef fect of SMU r F2 t argeting on Susceptibility to M eK inhibitor s in Melanoma

R. Marais, C. Wellbrock, I. Arozarena, 2012 .

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

K. Flaherty, J. Reis-Filho, Qiongqing Wang, 2012, The New England journal of medicine.

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

C. Springer, R. Marais, N. Dumaz, 2006, Cancer research.

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.

R. Marais, R. Hayward, A. Virós, 2012, Cancer discovery.

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

C. Springer, R. Marais, R. Lo, 2013, The Journal of investigative dermatology.

Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen

C. Marshall, P. Workman, S. Whittaker, 2006, Journal of biomolecular screening.

Lamin A/C controls nuclear matrin-3 levels and localization, but not alternative splicing of cassette exons

C. Gooding, Christopher W. J. Smith, R. Hayward, 2018, bioRxiv.

Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis

Glenn E. Morris, Ziyuan Lin, Huaqin Sun, 2017, Human molecular genetics.

Astrocytoma derived short-term cell cultures retain molecular signatures characteristic of the tumour in situ.

N. Potter, B. Harding, W. Harkness, 2009, Experimental cell research.

Essential but sparse collagen hydroxylysyl post-translational modifications detected by DNP NMR.

H. Oschkinat, R. Hayward, C. Shanahan, 2018, Chemical communications.

Filamentous nuclear actin regulation of PML NBs during the DNA damage response is deregulated by prelamin A

R. Hayward, C. Shanahan, R. Grosse, 2022, Cell death & disease.

Histology and immunohistochemistry

N. Dhomen, C. Springer, C. Pritchard, 2010 .

Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies

S. Whittaker, Arnaud Nourry, C. Springer, 2010, Science Translational Medicine.

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.

R. Marais, R. Hayward, A. Virós, 2012, Cancer discovery.

A mouse model of melanoma driven by oncogenic KRAS.

J. Reis-Filho, C. Milagre, N. Dhomen, 2010, Cancer research.

Tumor and Stem Cell Biology a Mouse Model of Melanoma Driven by Oncogenic Kras

J. Reis-Filho, C. Milagre, N. Dhomen, 2022 .

Filamentous particles in human alveolar cell carcinomas: electron microscopy studies of six cases (preliminary report).

R. Hayward, A. Leibovitz, J. Stinson, 1972, Journal of the National Cancer Institute.